TACTI-mel Patient Recruitment Complete & Operational Update
Filed with ASX · · 3 pages · English
Earlier from Immutep
- Immutep receives IND approval from US FDA for IMP321
- Immutep submits IND application with FDA
- Mid-point of patient enrolment reached in AIPAC trial
- Webcast slides for TACTI-mel clinical trial data
- Response to ASX Price Query
Later from Immutep
- Appendix 4E & 2018 Full Year Statutory Accounts
- Progress towards clinical development of IMP761
- Immutep enters into collaboration with Pfizer & Merck KGaA
- Positive interim TACTI-mel data presented at SITC
- Immutep granted European patent for IMP321
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep